Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa™ Platform
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com ...
Myriad RBM Joins Institut Pasteur in the Global Fight against Tuberculosis
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com ...
Institut Pasteur and Myriad RBM Publish Initial Results from Landmark Study of Immune Response
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com Institut Past...
DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration
DaVita Contact: Bianca Violante (303) 876-6614 bianca.violante@davita.com Investor Contact: Jim Gustafson (310) 536-2585 jim.gustafson@davita...
Myriad Announces Diabetes Collaboration with Sanofi – Press Release
Myriad Contacts Investor Relations: Jim Evans, Chief Financial Officer (801) 584-1143 investors@myriad.com Myriad RBM: Chris Martin, Director o...
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0
New panel expands Myriad RBM's cancer-related drug and companion diagnostic discovery service offering. Salt Lake City, UT (PRWEB) May 09, 2012...
Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine
Acquisition Expands Myriad's Leadership Position in Companion Diagnostics SALT LAKE CITY and AUSTIN, Texas, April 27, 2011 (GLOBE NEWSWIRE) -- Myri...